Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Total Liabilities (2021 - 2026)

Nuvectis Pharma has reported Total Liabilities over the past 6 years, most recently at $11.2 million for Q1 2026.

  • Quarterly results put Total Liabilities at $11.2 million for Q1 2026, up 21.58% from a year ago — trailing twelve months through Mar 2026 was $11.2 million (up 21.58% YoY), and the annual figure for FY2025 was $13.3 million, up 49.49%.
  • Total Liabilities reached $11.2 million in Q1 2026 per NVCT's latest filing, down from $13.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $13.3 million in Q4 2025 and bottomed at $2.7 million in Q2 2022.
  • Median Total Liabilities over the past 5 years was $6.2 million (2022), compared with a mean of $7.0 million.
  • Peak annual rise in Total Liabilities hit 9169.7% in 2022, while the deepest fall reached 49.71% in 2022.
  • Over 5 years, Total Liabilities stood at $6.2 million in 2022, then rose by 12.9% to $7.0 million in 2023, then rose by 27.35% to $8.9 million in 2024, then surged by 49.49% to $13.3 million in 2025, then fell by 15.93% to $11.2 million in 2026.
  • Business Quant data shows Total Liabilities for NVCT at $11.2 million in Q1 2026, $13.3 million in Q4 2025, and $11.6 million in Q3 2025.